These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

413 related items for PubMed ID: 9921806

  • 1. Reduction of acute renal allograft rejection by daclizumab. Daclizumab Double Therapy Study Group.
    Nashan B, Light S, Hardie IR, Lin A, Johnson JR.
    Transplantation; 1999 Jan 15; 67(1):110-5. PubMed ID: 9921806
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Cyclosporine-sparing effects of daclizumab in renal allograft recipients.
    Ingle GR, Moudgil A, Vo A, Jordan SC.
    Am J Health Syst Pharm; 2005 Feb 15; 62(4):391-6. PubMed ID: 15745891
    [Abstract] [Full Text] [Related]

  • 5. Daclizumab: a review of its use in the prevention of acute rejection in renal transplant recipients.
    Wiseman LR, Faulds D.
    Drugs; 1999 Dec 15; 58(6):1029-42. PubMed ID: 10651389
    [Abstract] [Full Text] [Related]

  • 6. Daclizumab prevents acute rejection and improves patient survival post transplantation: 1 year pooled analysis.
    Ekberg H, Bäckman L, Tufveson G, Tydén G, Nashan B, Vincenti F.
    Transpl Int; 2000 Dec 15; 13(2):151-9. PubMed ID: 10836653
    [Abstract] [Full Text] [Related]

  • 7. Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. Daclizumab Triple Therapy Study Group.
    Vincenti F, Kirkman R, Light S, Bumgardner G, Pescovitz M, Halloran P, Neylan J, Wilkinson A, Ekberg H, Gaston R, Backman L, Burdick J.
    N Engl J Med; 1998 Jan 15; 338(3):161-5. PubMed ID: 9428817
    [Abstract] [Full Text] [Related]

  • 8. A multicenter, open-label, comparative trial of two daclizumab dosing strategies vs. no antibody induction in combination with tacrolimus, mycophenolate mofetil, and steroids for the prevention of acute rejection in simultaneous kidney-pancreas transplant recipients: interim analysis.
    Stratta RJ, Alloway RR, Hodge E, Lo A, Pancreas Investigators Vital Outcomes Trial (PIVOT) Study Group.
    Clin Transplant; 2002 Feb 15; 16(1):60-8. PubMed ID: 11982617
    [Abstract] [Full Text] [Related]

  • 9. Basiliximab versus daclizumab combined with triple immunosuppression in deceased donor renal transplantation: a prospective, randomized study.
    Kandus A, Arnol M, Omahen K, Oblak M, Vidan-Jeras B, Kmetec A, Bren AF.
    Transplantation; 2010 Apr 27; 89(8):1022-7. PubMed ID: 20075788
    [Abstract] [Full Text] [Related]

  • 10. Daclizumab (humanized anti-IL2Ralpha mAb) prophylaxis for prevention of acute rejection in renal transplant recipients with delayed graft function.
    Bumgardner GL, Ramos E, Lin A, Vincenti F, Daclizumab Triple Therapy and Double Therapy Groups.
    Transplantation; 2001 Aug 27; 72(4):642-7. PubMed ID: 11544424
    [Abstract] [Full Text] [Related]

  • 11. Placebo-controlled study of a humanized anti-TAC monoclonal antibody in dual therapy for prevention of acute rejection after renal transplantation.
    Charpentier B, Thervet E.
    Transplant Proc; 1998 Jun 27; 30(4):1331-2. PubMed ID: 9636541
    [No Abstract] [Full Text] [Related]

  • 12. Pharmacokinetics of daclizumab and mycophenolate mofetil with cyclosporine and steroids in renal transplantation.
    Pescovitz MD, Bumgardner G, Gaston RS, Kirkman RL, Light S, Patel IH, Nieforth K, Vincenti F.
    Clin Transplant; 2003 Dec 27; 17(6):511-7. PubMed ID: 14756266
    [Abstract] [Full Text] [Related]

  • 13. Anti-interleukin-2 receptor antibodies for the prevention of rejection in pediatric renal transplant patients: current status.
    Swiatecka-Urban A.
    Paediatr Drugs; 2003 Dec 27; 5(10):699-716. PubMed ID: 14510627
    [Abstract] [Full Text] [Related]

  • 14. Improved efficacy of basiliximab over antilymphocyte globulin induction therapy in paediatric renal transplantation.
    Clark G, Walsh G, Deshpande P, Koffman G.
    Nephrol Dial Transplant; 2002 Jul 27; 17(7):1304-9. PubMed ID: 12105256
    [Abstract] [Full Text] [Related]

  • 15. Reduced exposure to calcineurin inhibitors in renal transplantation.
    Ekberg H, Tedesco-Silva H, Demirbas A, Vítko S, Nashan B, Gürkan A, Margreiter R, Hugo C, Grinyó JM, Frei U, Vanrenterghem Y, Daloze P, Halloran PF, ELITE-Symphony Study.
    N Engl J Med; 2007 Dec 20; 357(25):2562-75. PubMed ID: 18094377
    [Abstract] [Full Text] [Related]

  • 16. Daclizumab induction, tacrolimus, mycophenolate mofetil and steroids as an immunosuppression regimen for primary kidney transplant recipients.
    Ciancio G, Burke GW, Suzart K, Roth D, Kupin W, Rosen A, Olson L, Esquenazi V, Miller J.
    Transplantation; 2002 Apr 15; 73(7):1100-6. PubMed ID: 11965039
    [Abstract] [Full Text] [Related]

  • 17. Can daclizumab reduce acute rejection and improve long-term renal function in tacrolimus-based primary renal transplant recipients?
    Cheung CY, Liu YL, Wong KM, Chan HW, Chan YH, Wong HS, Chak WL, Choi KS, Chau KF, Shek CC, Li CS.
    Nephrology (Carlton); 2008 Jun 15; 13(3):251-5. PubMed ID: 18221256
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. A pilot study of steroid-free immunosuppression in the prevention of acute rejection in renal allograft recipients.
    Cole E, Landsberg D, Russell D, Zaltzman J, Kiberd B, Caravaggio C, Vasquez AR, Halloran P.
    Transplantation; 2001 Sep 15; 72(5):845-50. PubMed ID: 11571448
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.